In the present work, we explored potential adjuvants for a vaccine against Plasmodium. Working within the framework of an established preclinical model of susceptibility to Plasmodium, as is the infection of BALB/c mice by P. yoelii sporozoites (46, 47), and using the major vaccine lead candidate, CSP, we tested two new adjuvants for immunization against malaria, the TLR3 agonist poly(A:U), and 5’ppp-dsRNA, a RIG-I agonist. The gene discussed is TLR3; the disease is infection.